Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cemiplimab Maintenance in Advanced Adrenocortical Cancer
NCT07085572Phase 2Recruiting
- Sponsor
- ASST Spedali Civili di Brescia
- Start
- Sep 2025
- Primary completion
- Jul 2028
- Modality
- Immune Checkpoint Inhibitors, Antibody Conjugates, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 2 trial of cemiplimab in adrenocortical carcinoma (ACC), sponsored by ASST Spedali Civili di Brescia. Started Sep 2025; status: recruiting.
02
Drugs
cemiplimab
03
Conditions
adrenocortical carcinoma (ACC)
Beyond the preview
Go deeper on NCT07085572.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07085572.